Cell Source, Inc. (CLCS) stock
Close on Oct 19, 2026Market cap $21.99MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2025
Valuation
- Market cap
- $21.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$4.72M
- EPS, diluted
- -$0.14
- Book value per share
- -$0.45
- Diluted shares
- 45M
Trading
- Previous close
- $0.49
- Open
- $0.49
- Day's range
- $0.49 – $0.49
- Volume
- 800
- Average volume (20 days)
- 2,440
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLCS | S&P 500 | Difference | CLCS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.3% | +0.6% | −3.0 pts | ||
| 3 months | -43.2% | +3.4% | −46.6 pts | ||
| Year to date | -2.3% | +13.3% | −15.6 pts | ||
| 1 year | +22.1% | +16.6% | +5.5 pts | ||
| 3 years | -22.5% | +86.4% | −108.9 pts | -8.1% | +23.1% |
| 5 years | -61.3% | +81.9% | −143.1 pts | -17.3% | +12.7% |
| 10 years | -43.5% | +318.9% | −362.4 pts | -5.6% | +15.4% |
Thirteen years at a glance
Fiscal years 2012 to 2024 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
About Cell Source
Pharmaceutical Preparations
Cell Source, Inc. is a corporate entity organized under the laws of Nevada. The supplied annual report excerpt consists primarily of regulatory reporting identifiers, financial instruments, and accounting classifications, without disclosing information regarding specific commercial operations, products, services, operating segments, or customers.
Company profile, executives and historyCell Source stock: common questions
What is Cell Source's stock price?
CLCS closed at $0.49 on Oct 19, 2026, down 0.01% on the day.
What is Cell Source's market cap?
Cell Source was worth $21.99M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CLCS's P/E ratio?
Cell Source lost money over the twelve months to Mar 31, 2025 (diluted EPS -$0.14), so it has no meaningful P/E ratio.
Does Cell Source pay a dividend?
No. Cell Source has not paid a cash dividend over the last twelve months.
How has CLCS stock performed over the past year?
Including dividends, CLCS returned +22.1% over the past year, against +16.6% for the S&P 500.
Who are Cell Source's competitors?
Companies most similar to Cell Source by business, industry and size include HSTC, PPCB, AKTX, RADX, SNY.
See a number that looks wrong?